University of British Columbia

Qlt Phototherapeutics, Inc.

Other

Qlt Inc.

Quadra Logic Technologies, Inc.

The General Hospital Corporation

Massachusetts Eye and Ear Infirmary

Novartis Opthalmics Ag

Qlt, Inc. and

Ciba Vision Opthalmics

Qlt Phototherapeutices Inc.

Novartis Ag

Modestus Onuora Kay Obochi

Julia Levy

Julia G Levy

Anna M Richter

David H Dolphin

Ethan D Sternberg

David W Hunt

Agnes How-Ching Chan

Gustav Huber

Elizabeth M Waterfield

Modestus O Obochi

H Andrew Strong

Philippe Maria Clotaire Margaron

Guillermo O Simkin

Ashok Jain

Mario Fsadni

Ronald Erwin Boch

David W C Hunt

Janice North

Andrew Norman Tovey

Jack K Chow

Modestus O K Obochi

Simon Leong

Jack J Chow

William C Stewart

Jack Rootman

Howard E Meadows

Danielle Wenkstern

J Kevin Steele

Anthea T Stammers

Mario G Fsadni

Gustave Huber

Barbara Kelly

Christopher Richard Honey

Stephen Yip

Martin Renke

Claude A A Hariton

Marcello Nick Bussanich

David R Mallek

Joan W Miller

Tayyaba Hasan

Evangelos S Gragoudas

Beth Anne Allison

David J Granville

Philippe Maria Margaron

Jing-Song Tao

Ethan Sternberg

David Wc Hunt

Ursula Schmidt-Erfurth

Claude A Hariton

Patrick Mark Curry

Catriona Jamieson

P Haydn Pritchard

Evangelos S Gradoudas

David William Carey Hunt

Daniel Liu

Nick Bussanich

Claude Aa Hariton

Herma C Neyndorff

Jain Ashok

Andrew N Tovey

Alain H Curaudeau

Modestus Onuora Obochi

Photodynamic therapy of conditions of the eye, especially those conditions characterized by unwanted neovasculature, such as age-related macular degeneration, results in enhanced visual acuity for treated subjects.

Vision through photodynamic therapy of the eye

This invention relates generally to the field of pharmacotherapeutics and the use of photodynamic therapy ('PDT'). In particular, the invention provides a method for reducing or preventing the effects of inflammation arising from normal dose photodynamic therapy (PDT), which method comprises exposing a target tissue in a subject that has been treated with normal dose PDT treatment to low dose light having a wavelength absorbed by a photosensitizing agent used in said normal dose PDT treatment for a time sufficient to reduce or prevent the effects of inflammation arising from said normal dose PDT treatment. The method is particularly useful in reducing or preventing the effects of inflammation arising from normal dose PDT treatment of ocular tissues.

Method for reducing or preventing PDT related inflammation

Immuno-adjuvant photodynamic therapy to treat and prevent metastatic cancer is effected using photosensitizers in combination with immuno-adjuvants to destroy metastatic tumor cells.

Immuno-adjuvant PDT treatment of metastatic tumors

Multiple sclerosis and rheumatoid arthritis can be treated effectively using photodynamic therapy. In this protocol, a photoactive compound is administered, allowed to distribute in the effected subject, and the subject is then irradiated to activate the photoactive compound. Alternatively, the blood of a subject to be treated can be subjected to PDT extracorporeally. In the case of rheumatoid arthritis, localized treatment at the joints may also be employed.

Photodynamic therapy in selective cell inactivation in blood and treating immune dysfunction diseases

New compounds useful in photodynamic therapy are of the formula and their 1,4-diene isomersand the metallated and/or labeled and/or conjugated forms thereof

Ethylene glycol esters as photoactive agents

Methods, compositions and articles for reducing or preventing the effects of inflammation

Donor material from a xenogeneic source is modified to enhance its survival time in a recipient by treating the donor material using low-dose photodynamic therapy (PDT). The donor material, such as an organ or cell suspension, is treated with a photosensitizer and irradiated in a low-dose protocol before transplantation into a xenogeneic recipient.

Method to prevent xenograft transplant rejection

Photodynamic therapy to prevent secondary cataracts is effected using photosensitizers such as green porphyrins as photoactive agents to destroy remnant lens epithelial cells.

Use of photodynamic therapy for prevention of secondary cataracts

Methods to treat arterial plaque

Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor

Growing community of inventors

Vancouver, Canada

Julia G Levy